NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
MOZOBIL (plerixafor) by Sanofi is cxcr4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (sdf-1α). First approved in 2008.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOZOBIL (plerixafor) is a small-molecule hematopoietic stem cell mobilizer approved in 2008 that blocks the CXCR4 chemokine receptor, releasing CD34+ stem cells from bone marrow into circulation. It is used to mobilize autologous stem cells prior to collection and transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. The drug works by disrupting the SDF-1α/CXCR4 interaction that anchors hematopoietic stem cells to the marrow microenvironment.
$0.003BPart D
LOE ApproachingStable
Product approaching loss of exclusivity with modest Part D utilization and minimal claims volume; expect transition from growth-focused roles to lifecycle extension and generic transition planning.
Mechanism of Action
CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to…
Pharmacologic Class:
Hematopoietic Stem Cell Mobilizer
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)
Started Jul 2022
0COVID-19 Acute Respiratory Distress SyndromeCOVID-19
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Started Jun 2022
1 enrolled
Sickle Cell Disease
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
Started Oct 2021
53 enrolled
Autologous Haematopoietic Stem Cell Transplant
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Started Nov 2020
25 enrolled
Metastatic Pancreatic Cancer
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Started Dec 2018
21 enrolled
GlioblastomaGlioblastoma With Primitive Neuronal ComponentGliosarcoma+2 more
Worked on MOZOBIL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.